Burden of metastatic bone disease from genitourinary malignancies
(2010) In Expert Review of Anticancer Therapy 10(11). p.1721-1733- Abstract
- Bone metastases are common among patients with stage IV genitourinary cancers Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event These events are associated with increased medical expenses and decreased quality of life Current guidelines recommend screening for bone metastases in men with high-risk prostate cancer but guidance for screening and treatment of bone metastases from genitourinary cancers varies by country and setting Several bisphosphonates have been evaluated in the advanced genitourinary cancer setting Zoledronic acid has demonstrated efficacy in significantly reducing the risk of skeletal-related events in patients with bone metastases from a broad range... (More)
- Bone metastases are common among patients with stage IV genitourinary cancers Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event These events are associated with increased medical expenses and decreased quality of life Current guidelines recommend screening for bone metastases in men with high-risk prostate cancer but guidance for screening and treatment of bone metastases from genitourinary cancers varies by country and setting Several bisphosphonates have been evaluated in the advanced genitourinary cancer setting Zoledronic acid has demonstrated efficacy in significantly reducing the risk of skeletal-related events in patients with bone metastases from a broad range of solid tumors including prostate renal and bladder cancers and is recommended for preserving bone health (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1752479
- author
- Mulders, Peter F. ; Abrahamsson, Per-Anders LU and Bukowski, Ronald M.
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- targeted therapy, related events, skeletal, genitourinary cancer, bisphosphonates, bone metastases
- in
- Expert Review of Anticancer Therapy
- volume
- 10
- issue
- 11
- pages
- 1721 - 1733
- publisher
- Future Drugs Ltd
- external identifiers
-
- wos:000284495900012
- scopus:78649284751
- ISSN
- 1744-8328
- DOI
- 10.1586/ERA.10.136
- language
- English
- LU publication?
- yes
- id
- 2dbb2333-6d26-4f28-9f2d-e863cc07403f (old id 1752479)
- date added to LUP
- 2016-04-01 10:17:34
- date last changed
- 2022-01-25 21:50:32
@article{2dbb2333-6d26-4f28-9f2d-e863cc07403f,
abstract = {{Bone metastases are common among patients with stage IV genitourinary cancers Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event These events are associated with increased medical expenses and decreased quality of life Current guidelines recommend screening for bone metastases in men with high-risk prostate cancer but guidance for screening and treatment of bone metastases from genitourinary cancers varies by country and setting Several bisphosphonates have been evaluated in the advanced genitourinary cancer setting Zoledronic acid has demonstrated efficacy in significantly reducing the risk of skeletal-related events in patients with bone metastases from a broad range of solid tumors including prostate renal and bladder cancers and is recommended for preserving bone health}},
author = {{Mulders, Peter F. and Abrahamsson, Per-Anders and Bukowski, Ronald M.}},
issn = {{1744-8328}},
keywords = {{targeted therapy; related events; skeletal; genitourinary cancer; bisphosphonates; bone metastases}},
language = {{eng}},
number = {{11}},
pages = {{1721--1733}},
publisher = {{Future Drugs Ltd}},
series = {{Expert Review of Anticancer Therapy}},
title = {{Burden of metastatic bone disease from genitourinary malignancies}},
url = {{http://dx.doi.org/10.1586/ERA.10.136}},
doi = {{10.1586/ERA.10.136}},
volume = {{10}},
year = {{2010}},
}